Ignite Creation Date:
2025-12-24 @ 4:07 PM
Ignite Modification Date:
2025-12-30 @ 3:50 AM
Study NCT ID:
NCT00404066
Status:
COMPLETED
Last Update Posted:
2017-12-22
First Post:
2006-11-22
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Sponsor:
George Albert Fisher
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-10
Start Date Type:
None
Primary Completion Date:
2010-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-03
Completion Date Type:
ACTUAL
First Submit Date:
2006-11-22
First Submit QC Date:
None
Study First Post Date:
2006-11-27
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-02-03
Results First Submit QC Date:
None
Results First Post Date:
2017-12-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-11-28
Last Update Post Date:
2017-12-22
Last Update Post Date Type:
ACTUAL